Celsion Corporation to Hold Third Quarter 2020 Financial Results and Business Update Conference Call on Monday, November 16, ...
November 09 2020 - 8:30AM
Celsion Corporation (NASDAQ: CLSN) announced today that the Company
will host a conference call to discuss financial results for the
third quarter ended September 30, 2020 and provide an update on its
development programs for GEN-1, an IL-12 DNA plasmid vector
formulated into a nanoparticle with a non-viral delivery system and
ThermoDox®, its proprietary heat-activated liposomal encapsulation
of doxorubicin at 11:00 a.m. ET on Monday, November 16, 2020.
To participate in the call, interested parties
may dial 1-800-367-2403 (Toll-Free/North America) or 1-334-777-6978
(International/Toll) and ask for the Celsion Corporation Third
Quarter 2020 Earnings Call (Conference Code: 8337630) to register
ten minutes before the call is scheduled to begin. The call will
also be broadcast live on the internet at www.celsion.com. The call
will be archived for replay on Monday, November 16, 2020 and will
remain available until November 30, 2020. The replay can be
accessed at 1-719-457-0820 or 1-888-203-1112 using Conference ID:
8337630. An audio replay of the call will also be available on the
Company's website, www.celsion.com, for 90 days after 2:00 p.m. ET
Monday, November 16, 2020.
About Celsion Corporation
Celsion is a fully integrated oncology company
focused on developing a portfolio of innovative cancer treatments,
including immunotherapies, DNA-based therapies and directed
chemotherapies. The Company’s product pipeline includes GEN-1, a
DNA-based immunotherapy for the localized treatment of ovarian
cancer and ThermoDox®, a proprietary heat-activated liposomal
encapsulation of doxorubicin, currently in Phase III development
for the treatment of primary liver cancer and in development for
other cancer indications. Celsion has two feasibility stage
platform technologies for the development of novel nucleic
acid-based immunotherapies and other anti-cancer DNA or RNA
therapies. Both are novel synthetic, non-viral vectors with
demonstrated capability in nucleic acid cellular transfection. For
more information on Celsion, visit: http://www.celsion.com.
(CLSN-FIN).
Celsion wishes to inform readers that
forward-looking statements in this release are made pursuant to the
"safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Readers are cautioned that such forward-looking
statements involve risks and uncertainties including, without
limitation, unforeseen changes in the course of research and
development activities and in clinical trials; the uncertainties of
and difficulties in analyzing interim clinical data; the
significant expense, time, and risk of failure of conducting
clinical trials; the need for Celsion to evaluate its future
development plans; possible acquisitions or licenses of other
technologies, assets or businesses; possible actions by customers,
suppliers, competitors, regulatory authorities; and other risks
detailed from time to time in Celsion's periodic reports and
prospectuses filed with the Securities and Exchange Commission.
Celsion assumes no obligation to update or supplement
forward-looking statements that become untrue because of subsequent
events, new information or otherwise.
Celsion Investor Contact
LHA Investor Relations Jeffrey W.
Church
Kim Sutton Golodetz Executive Vice
President & CFO
212-838-3777 609-482-2455
kgolodetz@lhai.com
jchurch@celsion.com
# # #
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Apr 2023 to Apr 2024